Literature DB >> 3493292

Anti-tumor activity of class II MHC antigen-restricted cloned autoreactive T cells. II. Novel immunotherapy of B16 melanomas by local and systemic adoptive transfer.

T Shiohara, G Moellmann, K Jacobson, E Kuklinska, N H Ruddle, A B Lerner.   

Abstract

Lyt-1+, L3T4a+ autoreactive cloned T cells, producing lymphotoxin (LT) and interferon-gamma (IFN-gamma) in response to self-class II major histocompatibility complex antigen in vitro were examined for their anti-tumor effect in vivo against B16 melanomas. Without the aid of exogenous interleukin 2, the autoreactive T cells, when injected immediately and at an equal cell number into the site of s.c. inoculated B16 melanoma cells inhibited tumor growth in sublethally irradiated and nonirradiated syngeneic mice. The autoreactive T cells also induced regression of tumors established 3 days earlier. Normal spleen cells or class II-restricted cloned T cells specific for chicken gamma-globulin (CGG) had no inhibitory effect on tumor growth. A single injection of autoreactive T cells delayed tumor growth and prolonged the survival of mice that had received a lethal dose of B16 melanoma cells. The autoreactive T cells caused extensive necrosis at the injection site. A treatment regime consisting of two successive injections of anti-I-Ab monoclonal antibody 3JP prevented the inhibition of tumor growth, supporting the hypothesis that the autoreactive T cells inhibited the growth of melanomas by releasing LT and IFN-gamma upon recognition of I-A antigen-bearing cells at the injection site. The CGG-specific control T cells did not cause necrosis and survived within the nests of uninhibited tumor cells. Autoreactive T cells administered i.v. immediately after i.v. injection of B16 melanoma cells markedly reduced pulmonary metastases, whereas CGG-specific T cells did not. These results indicate that autoreactive T cells can function in vivo as inhibitors of tumor growth.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3493292

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

Review 1.  Induction and control of lichenoid tissue reactions.

Authors:  T Shiohara; N Moriya; M Nagashima
Journal:  Springer Semin Immunopathol       Date:  1992

2.  A novel strategy for targeting CD4+ PPD-reactive T cells against tumour cells using PPD monoclonal antibody heteroconjugates.

Authors:  A M Montgomery; M G Wing; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

3.  Autoreactive T-cell response to resting or activated B cells.

Authors:  J Moynihan; D Burstyn; M Zauderer
Journal:  Immunology       Date:  1989-10       Impact factor: 7.397

4.  Syngeneic lymph-node-targeting model of green fluorescent protein-expressing Lewis lung carcinoma.

Authors:  Vladimir Bobek; Katarina Kolostova; Daniela Pinterov; Michael Boubelik; Ping Jiang; Meng Yang; Robert M Hoffman
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

5.  Further characterization of a clinically relevant model of melanoma metastasis and an effective vaccine.

Authors:  D Shrayer; H Bogaars; V J Hearing; A Maizel; H Wanebo
Journal:  Cancer Immunol Immunother       Date:  1995-05       Impact factor: 6.968

6.  Loss of epidermal integrity by T cell-mediated attack induces long-term local resistance to subsequent attack. I. Induction of resistance correlates with increases in Thy-1+ epidermal cell numbers.

Authors:  T Shiohara; N Moriya; C Gotoh; J Hayakawa; M Nagashima; K Saizawa; H Ishikawa
Journal:  J Exp Med       Date:  1990-04-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.